1
|
Optimization of Wurster fluid bed coating: Mathematical model validated against pharmaceutical production data. POWDER TECHNOL 2021. [DOI: 10.1016/j.powtec.2021.03.059] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
2
|
Investigation of design space for freeze-drying injectable ibuprofen using response surface methodology. ACTA PHARMACEUTICA (ZAGREB, CROATIA) 2021; 71:81-98. [PMID: 32697744 DOI: 10.2478/acph-2021-0010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 04/05/2020] [Indexed: 01/19/2023]
Abstract
This study explores the use of a statistical model to build a design space for freeze-drying two formulations with ibuprofen. A 2 × 3 factorial experimental design was used to evaluate independent variables (filling volume and annealing time) and responses as residual moisture content, specific surface area and reconstitution time. A statistical model and response surface plots were generated to define the interactions among the selected variables. The models constructed for both formulations suggest that 1 mL of filled volume and no annealing should be used to achieve optimal residual moisture content, specific surface area and reconstitution time. The proposed models were validated with additional experiments, in which the responses observed were mainly in close agreement with the predicted ones. Additionally, the established models demonstrate the reliability of the evaluation procedure in predicting the selected responses.
Collapse
|
3
|
Li M, Sander S, Duan J, Rosencrance S, Miksinski SP, Yu L, Seo P, Rege B. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development. AAPS JOURNAL 2016; 18:1406-1417. [PMID: 27650190 DOI: 10.1208/s12248-016-9974-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 08/08/2016] [Indexed: 12/14/2022]
Abstract
This review presents scientific and regulatory considerations for the development of solid oral modified release (MR) drug products. It includes a rationale for patient-focused development based on Quality-by-Design (QbD) principles. Product and process understanding of MR products includes identification and risk-based evaluation of critical material attributes (CMAs), critical process parameters (CPPs), and their impact on critical quality attributes (CQAs) that affect the clinical performance. The use of various biopharmaceutics tools that link the CQAs to a predictable and reproducible clinical performance for patient benefit is emphasized. Product and process understanding lead to a more comprehensive control strategy that can maintain product quality through the shelf life and the lifecycle of the drug product. The overall goal is to develop MR products that consistently meet the clinical objectives while mitigating the risks to patients by reducing the probability and increasing the detectability of CQA failures.
Collapse
Affiliation(s)
- Min Li
- Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Sanna Sander
- Division of Modified Release Products, Office of Lifecycle Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - John Duan
- Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Susan Rosencrance
- Office of Lifecycle Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Sarah Pope Miksinski
- Office of New Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Lawrence Yu
- Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Paul Seo
- Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
| | - Bhagwant Rege
- Division of Modified Release Products, Office of Lifecycle Drug Products, Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA.
| |
Collapse
|
4
|
Rantanen J, Khinast J. The Future of Pharmaceutical Manufacturing Sciences. J Pharm Sci 2015; 104:3612-3638. [PMID: 26280993 PMCID: PMC4973848 DOI: 10.1002/jps.24594] [Citation(s) in RCA: 204] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 06/26/2015] [Accepted: 06/29/2015] [Indexed: 12/13/2022]
Abstract
The entire pharmaceutical sector is in an urgent need of both innovative technological solutions and fundamental scientific work, enabling the production of highly engineered drug products. Commercial-scale manufacturing of complex drug delivery systems (DDSs) using the existing technologies is challenging. This review covers important elements of manufacturing sciences, beginning with risk management strategies and design of experiments (DoE) techniques. Experimental techniques should, where possible, be supported by computational approaches. With that regard, state-of-art mechanistic process modeling techniques are described in detail. Implementation of materials science tools paves the way to molecular-based processing of future DDSs. A snapshot of some of the existing tools is presented. Additionally, general engineering principles are discussed covering process measurement and process control solutions. Last part of the review addresses future manufacturing solutions, covering continuous processing and, specifically, hot-melt processing and printing-based technologies. Finally, challenges related to implementing these technologies as a part of future health care systems are discussed.
Collapse
Affiliation(s)
- Jukka Rantanen
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
| | - Johannes Khinast
- Institute of Process and Particle Engineering, Graz University of Technology, Graz, Austria; Research Center Pharmaceutical Engineering, Graz, Austria.
| |
Collapse
|
5
|
Kundawala A, Sheth P, Maheshwari D. Sandwiched osmotic tablet for controlled release of metoprolol succinate. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2015. [DOI: 10.1007/s40005-015-0211-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Evaluating the effect of coating equipment on tablet film quality using terahertz pulsed imaging. Eur J Pharm Biopharm 2013; 85:1095-102. [DOI: 10.1016/j.ejpb.2013.03.019] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2012] [Revised: 03/05/2013] [Accepted: 03/17/2013] [Indexed: 11/18/2022]
|
7
|
Fonteyne M, Vercruysse J, Díaz DC, Gildemyn D, Vervaet C, Remon JP, Beer TD. Real-time assessment of critical quality attributes of a continuous granulation process. Pharm Dev Technol 2011; 18:85-97. [DOI: 10.3109/10837450.2011.627869] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach. Int J Pharm 2011; 421:220-9. [PMID: 21963471 DOI: 10.1016/j.ijpharm.2011.09.018] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Revised: 09/07/2011] [Accepted: 09/19/2011] [Indexed: 11/23/2022]
Abstract
Combining an amino acid and a sugar is a known strategy in the formulation of spray or freeze dried biomolecule powder formulations. The effect of the amino acid leucine in enhancing performance of spray-dried powders has been previously demonstrated, but interaction effects of several constituents which may provide multiple benefits, are less well-understood. A 3 factor 2 level (2(3)) factorial design was used to study the effects of leucine, glycine and alanine in a mannitol-based dry powder formulation on particle size, aerosolisation, emitted dose and cohesion. Other qualitative tests including scanning electronic microscopy and X-ray powder diffraction were also conducted on the design of experiment (DoE) trials. The results show that the use of glycine and/or alanine, though structurally related to leucine, did not achieve similar aerosol performance enhancing effects, rather the particle formation was hindered. However, when used in appropriate concentrations with leucine, the combination of amino acids produced an enhanced performance regardless of the presence of glycine and/or alanine, yielding significantly modified particle properties. The results from the DoE analyses also revealed the lack of linearity of effects for certain responses with a significant curvature in the model which would otherwise not be discovered using a trial-and-error approach.
Collapse
|
9
|
De Beer T, Wiggenhorn M, Hawe A, Kasper J, Almeida A, Quinten T, Friess W, Winter G, Vervaet C, Remon J. Optimization of a pharmaceutical freeze-dried product and its process using an experimental design approach and innovative process analyzers. Talanta 2011; 83:1623-33. [DOI: 10.1016/j.talanta.2010.11.051] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 11/01/2010] [Accepted: 11/22/2010] [Indexed: 11/25/2022]
|
10
|
Baldinger A, Clerdent L, Rantanen J, Yang M, Grohganz H. Quality by design approach in the optimization of the spray-drying process. Pharm Dev Technol 2011; 17:389-97. [DOI: 10.3109/10837450.2010.550623] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|